Burkhardt Glen's Form 4 filing
PhaseBio Pharmaceuticals Inc (PHAS) · filed May 24, 2022
- Accession no.
- 0001169245-22-000077
- Filed
- May 24, 2022
- Trade date
- May 20-23, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $8.89K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Burkhardt GlenCIK 0001803271 | Officer (SVP of Human Resources) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2022 | Common Stock | AGrant or awardAcquired | +11,248 | $0.68F2 | +$7,648.64 | 11,248 | Direct | |
| May 23, 2022 | Common Stock | SSaleDisposed | −11,248 | $0.79 | −$8,885.92 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
In accordance with the ESPP provisions, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 20, 2022.
Referenced by the price of 1 transaction in Table I.